



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

December 29, 2021

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Press Release

Enclosed please find Press Release relating to launch of the new product **Molupiravir 200 mg (Molunamax)** for the Indian market.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Ltd.

Sd/-

Sandeep Phadnis

**Vice President-Secretarial
& Company Secretary**

📍 **Registered Office:**
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
📠 +91 22 2431 5331 / 2431 5334
✉ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

JB Chemicals and Pharmaceuticals Limited to launch Molnupiravir 200 mg (Molunamax) for the Indian market

Mumbai, Dec 29, 2021 : JB Chemicals and Pharmaceuticals Limited, one of the fastest growing pharmaceutical companies in India is set to launch Molnupiravir 200 mg for the Indian market. Marketed under the brand name Molunamax, it will soon be available all across the country in the next month for the treatment of mild COVID-19.

Recently Molnupiravir, received U.S. FDA, Emergency Use Authorization(EUA) for the Treatment of Mild to Moderate COVID-19. Molnupiravir should be administered as soon as possible after a diagnosis of COVID-19 has been made, and within five days of symptom onset. In India, the CDSCO has recently recommended for grant of permission to manufacture and market Molnupiravir 200 mg capsule for restricted use under emergency situation in the country for treatment of patients above the age of 18 years, diagnosed COVID-19 positive, with SpO₂ > 93% and those who have a high risk of progression of the disease. The recommended dose for Molnupiravir is 800 mg (four 200 mg capsules) taken orally every 12 hours for five days, with or without food. Completion of the full five-day treatment course is important to maximize viral clearance and may help in minimizing the transmission of SARS-CoV-2.

Commenting on the launch, Nikhil Chopra, CEO & Whole time Director mentioned “We are glad to launch Molnupiravir for the Indian market. At a time when India is threatened with the possibility of a third wave, the launch of this product will significantly help the country in its fight against COVID-19. We will work closely with the healthcare professionals, government and medical communities to ensure Molnupiravir’s availability across the country so that no patient is left behind.”

About J.B. Chemicals & Pharmaceuticals Limited

J.B. Chemicals & Pharmaceuticals Limited is one of the fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has five brands among the top 300 brands in the country. The company exports its finished formulations to over 30 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks among the top 5 manufacturers globally in medicated and herbal lozenges.

📍 **Registered Office:**
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
☎ +91 22 2431 5331 / 2431 5334
✉ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

It has seven state of the art manufacturing facilities in India including a dedicated manufacturing facility for medicated lozenges. The manufacturing facilities are certified by leading regulators across the world.

#####

Media Contact

Ms. Sushree Mishra

J B Chemicals & Pharmaceuticals Ltd.

Tel : +91-9540663608

Email : corpcomm@jbcpl.com

Investor Contact

Mr. Shiv Muttoo

CDR India

Tel : +91-98335 57572

Email : Shiv@cdr-india.com

📍 **Registered Office:**
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
☎ +91 22 2431 5331 / 2431 5334
✉ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380